Benjamin Garmezy, MD

Benjamin Garmezy, MD, discusses some of the ongoing challenges or disparities seen in the community oncologist setting related to clinical trials.

A discussion on streamlining patient care processes between urologists and medical oncologists while maintaining treatment continuity and minimizing disruptions for patients with prostate cancer.

Experts share insights into collaborative relay strategies between urologists and medical oncologists that ensure smooth handoffs and continued care for patients with prostate cancer receiving combination therapies.

Explore the criteria for considering doublet or triplet therapies in advanced prostate cancer, examining their potential benefits and minimal added toxicity as discussed by key opinion leaders.

Key opinion leaders review the evolving landscape of metastatic HSPC, exploring the benefits and considerations of triplet combination therapies, including chemotherapy and ARPI agents.

David Morris, MD, FACS, and Benjamin Garmezy, MD, discuss treatment options, including ARPIs like enzalutamide and darolutamide, in nmCRPC, emphasizing the importance of personalized approaches for patient quality of life and outcome improvement.

Insight into the expanding landscape of hormone therapies, including androgen receptor inhibitors and biosynthesis inhibitors, and their diverse applications in prostate cancer treatment.

Key opinion leader Benjamin Garmezy, MD, discusses the shifting landscape of prostate cancer management, the importance of identifying lethal cases, and the challenges in risk stratification and prognosis.

Expert perspectives on the importance of forging collaborative relationships between urologists and medical oncologists in prostate cancer care, focusing on shared decision-making and patient-centric approaches.

Join David Morris, MD, FACS, and Benjamin Garmezy, MD, as they discuss their collaborative approach to treating advanced prostate cancer and the benefits it brings to patient care.

Benjamin Garmezy, MD, discusses the choice of third-line therapies in patients with advanced renal cell carcinoma.